Chest
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

Guest Access | Sign In via User Name/Password
This Article
Right arrow Full Text (PDF) Free
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Article Archive
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Coy, P
Right arrow Articles by Coldman, A.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Coy, P
Right arrow Articles by Coldman, A.

Chest, Vol 80, 453-458, Copyright © 1981 by American College of Chest Physicians

ARTICLES

Clinical indicators of prognosis in unresected lung cancer

P Coy, JM Elwood and AJ Coldman

A prognosis estimate in palliative treatment for inoperable lung cancer is thought to be of value. Performance status is now recognized as being of major importance, but only recently has been consistently available. We examined other simple information not requiring clinical or laboratory tests that is available in the clinical histories of a series of 1,839 patients with unresected lung cancer. Actuarial survivals at 1, 2, and 5 years were 21.9, 7.8, and 2.0 percent, respectively. The median survival rate was 24 weeks. Squamous cell histology and an increasing interval between the first symptoms and diagnosis were associated with a better prognosis. The number of symptoms recorded at the time of assessment had strong negative association with survival; asymptomatic patients had a two-year survival of 26 percent compared with 6 percent or less with four or more symptoms. A similar discrimination is given by Feinstein's index, which combines information on the number and type of symptoms and on the interval between first symptom and diagnosis. The clinical stage was strongly related to survival. Additional statistical analysis showed that the prognostic value of each of the most powerful prognostic factors, the number of symptoms, and Feinstein's index was little altered by the use of data on stage and histology in addition. The data show a range of median survival of 18 to 60 weeks for Feinstein's indices from 6 to 1, suggesting that the symptom index is useful particularly in the relatively well patients and the performance status particularly in those more ill. The combination may be better than either alone, and it is recommended that such information be recorded for all lung cancer patients.


This article has been cited by other articles:


Home page
 JCOHome page
M. H. Cullen, L. J. Billingham, C. M. Woodroffe, A. D. Chetiyawardana, N. H. Gower, R. Joshi, D. R. Ferry, R. M. Rudd, S. G. Spiro, J. E. Cook, et al.
Mitomycin, Ifosfamide, and Cisplatin in Unresectable Non–Small-Cell Lung Cancer: Effects on Survival and Quality of Life
J. Clin. Oncol., October 1, 1999; 17(10): 3188 - 3194.
[Abstract] [Full Text] [PDF]


HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1981 by the American College of Chest Physicians.